Serial Fecal Microbiota Transplant (FMT) Plus Fidaxomicin in the Treatment of Severe or Fulminant Clostridium Difficile Infection, With Detailed Characterization in Microbiota, Metabolomics and Host Immune Response
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Fidaxomicin (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 26 Jun 2019 Planned primary completion date changed from 16 Dec 2020 to 16 Dec 2021.
- 26 Jun 2019 Status changed from not yet recruiting to recruiting.
- 07 Dec 2018 New trial record